RIPK1 is a key mediator of inflammation (Mifflin et al., 2020), and a RIPK1 inhibitor (SAR443122) has been tested in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT04469621) to treat tissue damage resulting from inflammation in severe COVID‐19 patients. Here, RIPK1 is linked to COVID-19.